← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV18행 · 1개 프로그램
OverviewToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePhase 2
L-asparaginase, erwinia asparaginase (L-asparaginase, erwinia asparaginase)
Takeda·Acute Lymphoblastic Leukemia
30 trials
Overview
Program
L-asparaginase, erwinia asparaginase
Overview
Company
Takeda
Overview
Modality
CGT
Overview
Target
Acute Lymphoblastic Leukemia
Overview
Indication
Acute Lymphoblastic Leukemia; Lymphoma, Lymphoblastic
Overview
Phase
PHASE_2
Overview
Status
ACTIVE
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
Toxicology
Major finding
Patients First: Navigating Asparaginase-Based Treatment in Young Adults With Acute Lymphoblastic Leukemia.. This CME/CE integrates real patient stories, current evidence, evolving guideline recommendations, and expert clinical experience to equip hematology/oncology clinicians with practical strategies for successful asparaginase-based therapy in young adults with acute lymphoblastic leukemia (ALL…
Clinical
Safety signal
Patients First: Navigating Asparaginase-Based Treatment in Young Adults With Acute Lymphoblastic Leukemia.. This CME/CE integrates real patient stories, current evidence, evolving guideline recommendations, and expert clinical experience to equip hematology/oncology clinicians with practical strategies for successful asparaginase-based therapy in young adults with acute lymphoblastic leukemia (ALL…
Clinical
Selected reported efficacy
ORR 0.154%
Clinical
Reported ORR
0.154%
Clinical
Result source
ClinicalTrials.gov NCT00186875
Clinical
Program phase
PHASE_2
Clinical
Trial ref
NCT00186875